• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型移动应用程序(Heali)在肠易激综合征患者中的疾病治疗:随机对照初步试验。

A Novel Mobile App (Heali) for Disease Treatment in Participants With Irritable Bowel Syndrome: Randomized Controlled Pilot Trial.

机构信息

College of Health Solutions, Arizona State University, Phoenix, AZ, United States.

Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, United States.

出版信息

J Med Internet Res. 2021 Mar 2;23(3):e24134. doi: 10.2196/24134.

DOI:10.2196/24134
PMID:33650977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7967221/
Abstract

BACKGROUND

A diet high in fermentable, oligo-, di-, monosaccharides and polyols (FODMAPs) has been shown to exacerbate symptoms of irritable bowel syndrome (IBS). Previous literature reports significant improvement in IBS symptoms with initiation of a low FODMAP diet (LFD) and monitored reintroduction. However, dietary adherence to the LFD is difficult, with patients stating that the information given by health care providers is often generalized and nonspecific, requiring them to search for supplementary information to fit their needs.

OBJECTIVE

The aim of our study was to determine whether Heali, a novel artificial intelligence dietary mobile app can improve adherence to the LFD, IBS symptom severity, and quality of life outcomes in adults with IBS or IBS-like symptoms over a 4-week period.

METHODS

Participants were randomized into 2 groups: the control group (CON), in which participants received educational materials, and the experimental group (APP), in which participants received access to the mobile app and educational materials. Over the course of this unblinded online trial, all participants completed a battery of 5 questionnaires at baseline and at the end of the trial to document IBS symptoms, quality of life, LFD knowledge, and LFD adherence.

RESULTS

We enrolled 58 participants in the study (29 in each group), and 25 participants completed the study in its entirety (11 and 14 for the CON and APP groups, respectively). Final, per-protocol analyses showed greater improvement in quality of life score for the APP group compared to the CON group (31.1 and 11.8, respectively; P=.04). Reduction in total IBS symptom severity score was 24% greater for the APP group versus the CON group. Although this did not achieve significance (-170 vs -138 respectively; P=.37), the reduction in the subscore for bowel habit dissatisfaction was 2-fold greater for the APP group than for the CON group (P=.05).

CONCLUSIONS

This initial study provides preliminary evidence that Heali may provide therapeutic benefit to its users, specifically improvements in quality of life and bowel habits. Although this study was underpowered, findings from this study warrant further research in a larger sample of participants to test the efficacy of Heali app use to improve outcomes for patients with IBS.

TRIAL REGISTRATION

ClinicalTrials.gov NCT04256551; https://clinicaltrials.gov/ct2/show/NCT04256551.

摘要

背景

高发酵、寡糖、二糖、单糖和多元醇(FODMAPs)的饮食已被证明会加重肠易激综合征(IBS)的症状。先前的文献报道,低 FODMAP 饮食(LFD)的起始和监测再引入可显著改善 IBS 症状。然而,LFD 的饮食依从性是困难的,患者表示,医疗保健提供者提供的信息通常是笼统和非特异性的,需要他们搜索补充信息以满足他们的需求。

目的

我们的研究旨在确定新型人工智能饮食移动应用程序 Heali 是否可以改善成人 IBS 或 IBS 样症状患者在 4 周内对 LFD 的依从性、IBS 症状严重程度和生活质量结果。

方法

参与者被随机分为 2 组:对照组(CON),参与者接受教育材料;实验组(APP),参与者可访问移动应用程序和教育材料。在这项非盲在线试验过程中,所有参与者在基线和试验结束时完成了一套 5 份问卷,以记录 IBS 症状、生活质量、LFD 知识和 LFD 依从性。

结果

我们招募了 58 名参与者参加这项研究(每组 29 名),其中 25 名参与者完成了整个研究(CON 组 11 名,APP 组 14 名)。最终,按方案分析显示,APP 组的生活质量评分改善优于 CON 组(分别为 31.1 和 11.8;P=.04)。APP 组的 IBS 总症状严重程度评分降低了 24%,而 CON 组降低了 17%。虽然这没有达到显著差异(分别为-170 与-138;P=.37),但 APP 组对肠道习惯不满意的亚评分降低了 2 倍,而 CON 组降低了 1 倍(P=.05)。

结论

这项初步研究提供了初步证据,表明 Heali 可能为其用户提供治疗益处,特别是在生活质量和肠道习惯方面。尽管这项研究的效力不足,但这项研究的结果需要在更大的参与者样本中进行进一步研究,以测试 Heali 应用程序使用改善 IBS 患者结局的疗效。

试验注册

ClinicalTrials.gov NCT04256551;https://clinicaltrials.gov/ct2/show/NCT04256551。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f63/7967221/867cd23d964a/jmir_v23i3e24134_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f63/7967221/5c10533f2907/jmir_v23i3e24134_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f63/7967221/867cd23d964a/jmir_v23i3e24134_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f63/7967221/5c10533f2907/jmir_v23i3e24134_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f63/7967221/867cd23d964a/jmir_v23i3e24134_fig2.jpg

相似文献

1
A Novel Mobile App (Heali) for Disease Treatment in Participants With Irritable Bowel Syndrome: Randomized Controlled Pilot Trial.一种新型移动应用程序(Heali)在肠易激综合征患者中的疾病治疗:随机对照初步试验。
J Med Internet Res. 2021 Mar 2;23(3):e24134. doi: 10.2196/24134.
2
Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.基于网络的低 FODMAP 饮食与益生菌治疗肠易激综合征的长期疗效,包括对微生物组的 shotgun 分析:随机、双交叉临床试验。
J Med Internet Res. 2021 Dec 14;23(12):e30291. doi: 10.2196/30291.
3
A low fermentable oligo-di-mono saccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients.低可发酵寡糖、双糖、单糖和多元醇(FODMAP)饮食可减轻纤维肌痛患者的疼痛并改善其日常生活。
Scand J Pain. 2016 Oct;13:166-172. doi: 10.1016/j.sjpain.2016.07.004. Epub 2016 Aug 22.
4
Low fermentable oligo-di-mono-saccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled trial.低发酵性寡糖-二糖-多元醇饮食与腹泻型肠易激综合征患者的一般饮食建议比较:一项随机对照试验。
J Gastroenterol Hepatol. 2018 Jun;33(6):1192-1199. doi: 10.1111/jgh.14051. Epub 2018 Feb 21.
5
The long-term effect and adherence of a low fermentable oligosaccharides disaccharides monosaccharides and polyols (FODMAP) diet in patients with irritable bowel syndrome.患有肠易激综合征患者的低可发酵性寡糖、双糖、单糖和多元醇(FODMAP)饮食的长期效果和依从性。
J Hum Nutr Diet. 2020 Apr;33(2):159-169. doi: 10.1111/jhn.12706. Epub 2019 Oct 22.
6
Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome: A prospective, randomized trial.低可发酵寡糖、双糖、单糖和多元醇饮食用于腹泻型肠易激综合征患者:一项前瞻性随机试验。
J Gastroenterol Hepatol. 2021 Aug;36(8):2107-2115. doi: 10.1111/jgh.15410. Epub 2021 Feb 4.
7
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.低 FODMAP 饮食联合传统饮食建议与低碳水化合物饮食或药物治疗对肠易激综合征的疗效比较(CARIBS):一项单中心、单盲、随机对照试验。
Lancet Gastroenterol Hepatol. 2024 Jun;9(6):507-520. doi: 10.1016/S2468-1253(24)00045-1. Epub 2024 Apr 18.
8
A diet low in fermentable oligo-, di-, monosaccharides and polyols improves abdominal and overall symptoms in persons with all subtypes of irritable bowel syndrome.低发酵寡糖、二糖、单糖和多元醇饮食可改善所有亚型肠易激综合征患者的腹部和整体症状。
Neurogastroenterol Motil. 2024 Aug;36(8):e14845. doi: 10.1111/nmo.14845. Epub 2024 Jun 17.
9
Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial.低 FODMAP 饮食可减轻肠易激综合征的胃肠道症状,且临床应答可根据症状严重程度预测:一项随机交叉试验。
Clin Nutr. 2022 Dec;41(12):2792-2800. doi: 10.1016/j.clnu.2022.11.001. Epub 2022 Nov 4.
10
Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome.低 FODMAP 饮食盲法随机再引入阶段对肠易激综合征的疗效和发现。
Gastroenterology. 2024 Jul;167(2):333-342. doi: 10.1053/j.gastro.2024.02.008. Epub 2024 Feb 23.

引用本文的文献

1
Dietary management of irritable bowel syndrome: considerations, challenges, and solutions.肠易激综合征的饮食管理:考虑因素、挑战与解决方案。
Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1147-1161. doi: 10.1016/S2468-1253(24)00238-3.
2
Digital Health Interventions Are Effective for Irritable Bowel Syndrome Self-Management: A Systematic Review.数字健康干预对肠易激综合征自我管理有效:一项系统综述。
Dig Dis Sci. 2025 Feb;70(2):644-664. doi: 10.1007/s10620-024-08672-7. Epub 2024 Oct 14.
3
DOMINO trial analysis: evaluation of the diet effects on symptoms in IBS subtypes.

本文引用的文献

1
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.全球功能性胃肠病的流行情况和负担:罗马基金会全球研究结果。
Gastroenterology. 2021 Jan;160(1):99-114.e3. doi: 10.1053/j.gastro.2020.04.014. Epub 2020 Apr 12.
2
Marshall and Warren Lecture 2019: A paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment.2019 年马歇尔和沃伦讲座:肠易激综合征病理生理基础的范式转变及其对治疗的影响。
J Gastroenterol Hepatol. 2020 May;35(5):712-721. doi: 10.1111/jgh.15032. Epub 2020 Mar 27.
3
Achieving Rapid Blood Pressure Control With Digital Therapeutics: Retrospective Cohort and Machine Learning Study.
多米诺试验分析:评估饮食对肠易激综合征亚型症状的影响。
Therap Adv Gastroenterol. 2024 Jul 30;17:17562848241255296. doi: 10.1177/17562848241255296. eCollection 2024.
4
Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature review.肠易激综合征患者的工作相关问题及心理社会特征:文献综述更新
Biopsychosoc Med. 2024 May 15;18(1):12. doi: 10.1186/s13030-024-00309-5.
5
Gut liver brain axis in diseases: the implications for therapeutic interventions.肠道-肝脏-脑轴在疾病中的作用:治疗干预的意义。
Signal Transduct Target Ther. 2023 Dec 6;8(1):443. doi: 10.1038/s41392-023-01673-4.
6
Gut Symptoms during FODMAP Restriction and Symptom Response to Food Challenges during FODMAP Reintroduction: A Real-World Evaluation in 21,462 Participants Using a Mobile Application.肠道症状在 FODMAP 限制期间和 FODMAP 再引入期间食物挑战后的症状反应:使用移动应用程序对 21462 名参与者进行的真实世界评估。
Nutrients. 2023 Jun 9;15(12):2683. doi: 10.3390/nu15122683.
7
mHealth Intervention for Improving Pain, Quality of Life, and Functional Disability in Patients With Chronic Pain: Systematic Review.移动医疗干预对改善慢性疼痛患者疼痛、生活质量和功能障碍的系统评价。
JMIR Mhealth Uhealth. 2023 Feb 2;11:e40844. doi: 10.2196/40844.
8
A preliminary study of further attempt at the development, testing and application of an independent primary screening stool card.进一步尝试开发、测试和应用独立的初级粪便筛查卡的初步研究。
Sci Rep. 2022 Dec 21;12(1):22046. doi: 10.1038/s41598-022-26649-2.
9
Randomized Controlled Trials of Artificial Intelligence in Clinical Practice: Systematic Review.人工智能在临床实践中的随机对照试验:系统评价。
J Med Internet Res. 2022 Aug 25;24(8):e37188. doi: 10.2196/37188.
10
Understanding the user: Patients' perception, needs, and concerns of health apps for chronic constipation.了解用户:慢性便秘患者对健康应用程序的认知、需求和担忧。
Digit Health. 2022 May 29;8:20552076221104673. doi: 10.1177/20552076221104673. eCollection 2022 Jan-Dec.
通过数字疗法实现快速血压控制:回顾性队列研究与机器学习研究
JMIR Cardio. 2019 Mar 12;3(1):e13030. doi: 10.2196/13030.
4
Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions.腹泻型肠易激综合征的管理:非药物和药物干预综述
Therap Adv Gastroenterol. 2019 Oct 4;12:1756284819878950. doi: 10.1177/1756284819878950. eCollection 2019.
5
Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study.数字生物标志物的出现可预测和改善治疗效果:机器学习研究。
BMJ Open. 2019 Jul 23;9(7):e030710. doi: 10.1136/bmjopen-2019-030710.
6
Artificial intelligence powers digital medicine.人工智能推动数字医学发展。
NPJ Digit Med. 2018 Mar 14;1:5. doi: 10.1038/s41746-017-0012-2. eCollection 2018.
7
How Patients with IBS Use Low FODMAP Dietary Information Provided by General Practitioners and Gastroenterologists: A Qualitative Study.IBS 患者如何使用全科医生和胃肠病学家提供的低 FODMAP 饮食信息:一项定性研究。
Nutrients. 2019 Jun 11;11(6):1313. doi: 10.3390/nu11061313.
8
Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy.功能性胃肠病的个体化医学:从发病机制理解提高诊断和治疗效果。
World J Gastroenterol. 2019 Mar 14;25(10):1185-1196. doi: 10.3748/wjg.v25.i10.1185.
9
Low-FODMAP Diet Is Associated With Improved Quality of Life in IBS Patients-A Prospective Observational Study.低 FODMAP 饮食与 IBS 患者生活质量的改善相关:一项前瞻性观察研究。
Nutr Clin Pract. 2019 Aug;34(4):623-630. doi: 10.1002/ncp.10233. Epub 2019 Jan 15.
10
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.美国胃肠道、肝脏和胰腺疾病的负担和成本:2018 年更新。
Gastroenterology. 2019 Jan;156(1):254-272.e11. doi: 10.1053/j.gastro.2018.08.063. Epub 2018 Oct 10.